Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany
Differences between patient characteristics and dosing patterns were observed between patients with PsA and axSpA in Sweden and Germany. Treatment variations may reflect high prevalences of co-diagnoses, like psoriasis, or unmet therapeutic needs. This work serves as a first step towards future research for personalized treatment approaches to optimize treatment outcomes.
Authors
- Christoph Abé (ORCID: https://orcid.org/0000-0002-1680-8480)
- Sarah Welby (ORCID: https://orcid.org/0000-0003-3217-9490)
- Alexander Rieem Dun (ORCID: https://orcid.org/0000-0002-8182-5682)
- Thomas Wilke (ORCID: https://orcid.org/0000-0001-8263-7758)
- Jie Song (ORCID: https://orcid.org/0000-0002-7357-2136)
- Alexandra Cooper (ORCID: https://orcid.org/0000-0002-6087-7782)
- H. Roqué
- Scarlette Kienzle
Institutions
- Karolinska Institutet (SE)
- Logistics Management Institute (United States) (US)
- Quantify Research (Sweden) (SE)
- UCB Pharma (Belgium) (BE)
- Cytel (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1007/s12325-025-03216-5
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- UCB